Molecular genetic analysis of non-astrocytic gliomas

Histopathology

Volumn 34, Issue 4, 1999, Pages 331-341

  Tong, C Y K ^b   Ng, H K ^a   Pang, J C S ^b   Hui, A B Y ^b   Ko, H C W ^b   Lee, J C K ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b NONE

Author keywords

Apoptosis; Ependymomas; MDM2; Oligodendrogliomas; P53; PTEN MMAC1

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; BRAIN BIOPSY; CHROMOSOME 10Q; CLINICAL ARTICLE; FEMALE; GENE LOCATION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; TUMOR BIOPSY;

ADOLESCENT; ADULT; AGED; APOPTOSIS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; CHROMOSOMES, HUMAN, PAIR 10; FEMALE; GENES, P53; GLIOMA; HUMANS; INFANT; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PHOSPHORIC MONOESTER HYDROLASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; PTEN PHOSPHOHYDROLASE; TUMOR SUPPRESSOR PROTEINS;

EID: 0032917543     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1999.00603.x     Document Type: Article

References (53)

1. 1. Louis DN. A molecular genetic model of astrocytoma histopathology. Brain Pathol. 1997; 7; 755-764.
2. 2. von Deimling A, Louis DN, von Ammon K et al. Association of epidermal growth factor receptor gene amplification with loss of chromosome 10 in human glioblastoma multiforme. J. Neurosurg. 1992; 77; 295-301.
3. 3. Bello MJ, Leone PE, Vaquero J et al. Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors. Int. J. Cancer 1995; 64; 207-210.
4. 4. Reifenberger G, Kros JM, Schiffer D, Collins VP. Oligodendroglioma. Anaplastic oligodendrogliomas. In Kleihues PC and Cavanee WK eds. Pathology & Genetics. Tumours of the Nervous System. Lyon: International Agency for Cancer Research, 1997; 38-45.
5. 5. Zhu JJ, Santarius T, Wu X et al. Screening for loss of heterozygosity and microsatellite instability in oligodendrogliomas. Genes Chromo. Cancer 1998: 21; 207-16.
6. 6. Bijlsma EK, Voesten AM, Bijleveld EH et al. Molecular analysis of genetic changes in ependymomas. Genes Chromo. Cancer 1995; 13; 272-277.
7. 7. Birch BD, Johnson JP, Parsa A et al. Frequent type 2 neurofibromatosis gene transcript mutations in sporadic intramedullary spinal cord ependymoma. Neurosurgery 1996; 39; 135-140.
8. 8. Schiffer D, Wiestler OD. Ependymoma and variants. Anaplastic ependymoma. In Kleihues PC and Cavanee WK eds. Pathology & Genetics. Tumours of the Nervous System. Lyon: International Agency for Cancer Research, 1997; 50-54.
9. 9. Maintz D, Fiedler K, Koopmann J et al. Molecular genetic evidence for subtypes of oligoastrocytomas. J. Neuropathol. Exp. Neurol. 1997; 56; 1098-1104.
10. 10. Ohgaki H, Schauble B, zur Hausen A, von Ammon K, Kleihues P. Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Arch. 1995; 427; 113-118.
11. 11. Steck PA, Ligon AH, Cheong P, Yung WKA, Pershouse MA. Two tumour suppressive loci on chromosome 10 involved in human glioblastomas. Genes Chromo. Cancer 1995; 12; 255-261.
12. 12. Li J. Yen C, Liaw D et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 1997; 275; 1943-1947.
13. 13. Steck PA, Pershouse MA, Jasser SA et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genet. 1997; 15; 356-362.
14. 14. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM. Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998; 280; 1614-1617.
15. 15. Wang SI, Puc J, Li J et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res. 1997; 37; 4183-4186.
16. 16. Reifenberger J, Reifenberger G, Ischimura K, Schmidt EE, Wechsler W, Collins VP. Epidermal growth factor receptor expression in oligodendroglial tumors. Am. J. Pathol. 1996; 149; 29-35.
17. 17. Picksley SM, Lane DP. The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays 1993; 15; 689-690.
18. 18. Smith ML, Fornace AJ Jr. The two faces of tumor suppressor p53. Am. J. Pathol. 1996; 148; 1019-1022.
19. 19. Kleihues P, Burger PC, Scheithauer BW. Histological Typing of Tumours of the Central Nervous System. Berlin: Springer-Verlag, 1993.
20. 20. Reifenberger G, Kros JM, Schiffer D, Collins VP. Mixed gliomas. In Klethues P and Cavance WK eds. Pathology & Genetics, Tumours of the Nervous System. Lyon: International Agency for Research on Cancer, 1997; 45-47.
21. 21. Hart MN, Petito CK, Earle KM. Mixed gliomas, Cancer 1973; 33; 134-40.
22. 22. Rosenblum MK, Bibao JM, Ang LC. Neuromuscular system. In Rosai J ed. Ackerman's Surgical Pathology. 8th edn. St. Louis: Mosby, 1996; 2294.
23. nd edn. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1989.
24. 24. Hse IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350; 427-428.
25. 25. Okamoto A, Sameshima Y, Yokoyama S et al. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res. 1991; 51; 5171-5176.
26. 26. Ng HK, Lo KW, Huang DP, Poon WS. p53 in low-grade gliomas. Int. J. Surg. Pathol. 1994; 1; 163-170.
27. 27. Hunter SB, Abbott K, Varma VA, Olson JJ, Barnett DW, James CD. Reliability of differential PCR for the detection of EGFR and MDM2 gene amplification in DNA extracted from FFPE glioma tissue. J. Neuropathol. Exp. Neurol. 1995; 54; 57-64.
28. 28. Ng HK, Chen L. Apoptosis is associated with atypical/malignant change in meningiomas. An in situ labelling and immunohistochemical study. Histopathology 1998; 33; 64-70.
29. 29. Wharton SB, Hamilton FA, Chan WK, Anderson JR. Proliferation and cell death in oligodendrogliomas. Neuropathol. Appl. Neurobiol. 1998; 24; 21-28.
30. 30. Schiffer D, Dutto A, Cavalla P, Chio A, Migheli A, Piva R. Role of apoptosis in the prognosis of oligodendrogliomas. Neurochem. Int. 1997; 31; 245-250.
31. 31. Ransom DT, Ritland SR, Kimmel DW et al. Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas. Genes Chromo. Cancer 1992; 5; 348-356.
32. 32. Griffin CA, Long PP, Carson BS, Brem H. Chromosome abnormalities in low-grade central nervous system tumors, Cancer Genet. Cytogenet. 1992; 60; 67-73.
33. 33. Rey JA, Bello MJ. de Campos JM, Kusak ME, Moreno S. Chromosomal composition of a series of 22 human low-grade gliomas. Cancer Genet. Cytogenet. 1987; 29; 223-237.
34. 34. Hamilton RL, Pollack IF. The molecular biology of ependymomas. Brain Pathol. 1997; 7; 807-22.
35. 35. Mollenhauer J. Wiemann S, Scheurlen W et al. DMBT1, a new member of the SRCR superfamily, on chromosome 10q25.3-26.1 is deleted in malignant brain tumours. Nature Genet. 1997; 17; 32-40.
36. 36. Maier D, Comparone D, Taylor E et al. New deletion in low-grade oligodendroglioma at the glioblastoma suppressor locus on chromosome 10q25-16. Oncogene 1997; 15; 997-1000.
37. 37. Rasheed BKA, Stenzel TT, McLendon RE. PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res. 1997; 37; 4187-90.
38. 38. Duerr EM, Rollbrocker B. Hayashi Y et al. PTEN mutations in gliomas and glioneuronal tumors. Oncogene 1998; 16; 2259-2264.
39. 39. Whang YE, Wu X, Suzuki H et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl Acad. USA 1998; 95; 5246-5250.
40. 40. Louis DN. The p53 gene and protein in human brain tumors. J. Neuropathol. Exp. Neurol. 1994; 53; 11-21.
41. 41. Reifenberger J, Ring GU, Gies U et al. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J. Neuropathol. Exp. Neurol. 1996; 55; 822-31.
42. 42. Ohgaki H, Eibl RH, Wiestler OD, Yasargil MG, Newcomb EW, Kleihues P. p53 mutations in nonastrocytic human brain tumors. Cancer Res. 1992; 51; 6202-6205.
43. 43. Hagel C, Laking G, Laas R et al. Demonstration of p53 protein and TP53 gene mutations in oligodendrogliomas. Eur. J. Cancer 1996; 32A; 2242-8.
44. 44. Pavelic J. Hlavka V. Poljak M, Gale N, Pavelic K. p53 immunoreactivity in oligodendrogliomas. J. Neuro-oncol. 1994; 22; 1-6.
45. 45. Kraus JA, Koopmann J. Kaskel P et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J. Neuropathol. Exp. Neurol. 1995; 54; 91-5.
46. 46. Burger PC, Scheithauer BW. Atlas of Tumor Pathology. Tumors of the Central Nervous System. Washington, DC: Armed Forces Institute of Pathology, 1993; 142-144.
47. 47. McLendon RE, Enterline DS, Tien RD, Thorstad WL, Bruner JM. Tumors of central neuroepithelial origin. In Bigner DD, McLendon RE and Bruner JM eds. Russell and Rubinstein's Pathology of Tumors of the Nervous System, 6th edn. London: Edward Arnold, 1998; 382-386.
48. 48. Fink KL, Rushing EJ, Schold SC Jr, Nisen PD. Infrequency of p53 gene mutations in ependymomas. J. Neuro-oncol. 1996; 27; 111-115.
49. 49. Tominaga T, Kayama T, Kumabe T, Sonoda Y, Yoshimoto T. Anaplastic ependymomas: clinical features and tumour suppressor p53 gene analysis. Acta Neurochir. 1995; 135; 163-170.
50. 50. Leach FS, Tokino T, Meltzer P et al. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 1993; 53; 2231-2234.
51. 51. Reifenberger G, Liu L, Ichimura K, Schmidt EE, Collins VP, Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 1993; 53; 2736-2739.
52. 52. Pomerantz J, Schreiber-Agus N, Liegeois NJ et al. The INK4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998; 92; 713-723.
53. 55. Symonds H, Krall L, Remington L et al. P53 dependent apoptosis suppresses tumor growth and progression in vivo. Cell 1994; 78; 701-711.